A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight

Part of paid clinical trials in Miami, Florida.

Sponsor
Eli Lilly and Company
Study ID
NCT06824051
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overweight. Participation in the study will last approximately 8 months.

Key Dates

Start date
Feb 17, 2025
Status verified
Feb 2026
Primary completion
Jan 26, 2026
Completion
Jan 26, 2026

Study Design

Enrollment
120 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron
    Participants will receive orforglipron orally
  • Placebo Comparator: Placebo
    Participants will receive placebo orally

Primary Outcome Measure

Percent Change from Baseline in Visceral Adipose Tissue (VAT) [ Time Frame: Baseline, Week 36 ]

Locations (4)

FacilityCityStateZIPSite coordinators
Clinical Pharmacology of MiamiMiamiFlorida33172-
AxisDilworthMinnesota56529-
Ohio Clinical TrialsColumbusOhio43212-
Endeavor Clinical TrialsSan AntonioTexas78240-

Find similar trials in Miami, FL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Clinical Pharmacology of Miami· Miami, FLAxis· Dilworth, MNOhio Clinical Trials· Columbus, OHEndeavor Clinical Trials· San Antonio, TX

Related Studies